Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase 3 Trial Evaluating the Safety & Efficacy of IP IMNN-001 Administered in Combination w/ Standard Neoadjuvant & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

Next Previous
Trial Profile

A Randomized Phase 3 Trial Evaluating the Safety & Efficacy of IP IMNN-001 Administered in Combination w/ Standard Neoadjuvant & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 May 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMNN 001 (Primary) ; Carboplatin; Niraparib; Olaparib; Paclitaxel
  • Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Sarcoma
  • Focus Registrational; Therapeutic Use
  • Acronyms OVATION 3
  • Sponsors Imunon

Most Recent Events

  • 12 May 2026 According to an Imunon media release, FDA has reviewed and is aligned with Phase 3 protocol, confirms path to BLA Filing.
  • 12 May 2026 According to an Imunon media release, an enrollment in the Phase 3 OVATION 3 Study of IMNN-001 is expected to be completed by Q1 2029.
  • 05 May 2026 According to an Imunon media release, Company will host a conference call at 11:00 a.m. EDT on Tuesday, May 12, 2026 to discuss progress in advancing Phase 3 clinical development of its lead candidate IMNN-001 in newly diagnosed advanced ovarian cancer.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top